Shares of Hims & Hers Health Inc. (HIMS) plunged 18.56% in pre-market trading on Monday, following news that pharmaceutical giant Novo Nordisk has terminated its collaboration with the company. This unexpected development has significantly impacted investor sentiment towards the telehealth and wellness company.
Novo Nordisk announced that Hims & Hers Health will no longer have direct access to Wegovy®, a popular weight loss drug, via the NovoCare® Pharmacy. This termination of collaboration is likely to affect Hims & Hers Health's ability to offer this sought-after medication to its customers, potentially impacting its revenue stream and growth prospects in the weight management sector.
The sharp decline in Hims & Hers Health's stock price reflects investors' concerns about the company's future performance without access to Novo Nordisk's weight loss drug. As the healthcare sector continues to evolve, this development underscores the importance of strategic partnerships and product offerings in the competitive telehealth market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.